HomeNDC LookupDrug shortages › Tiagabine Hydrochloride Tablet

Tiagabine Hydrochloride Tablet shortage

Tiagabine Hydrochloride Tablet is currently listed in shortage by the FDA. The FDA lists 4 affected products. This page was last refreshed from FDA data on Sep 23, 2026.

To Be Discontinued ⚠ Supply risk: High Neurology 4 products 161 days First posted Apr 15, 2026 Updated Apr 15, 2026
Here’s the bottom line

Teva is permanently stopping production of tiagabine hydrochloride tablets. Other makers — including Sun Pharmaceutical and Novadoz — have not reported a shortage and still list 2 mg and 4 mg strengths, though 12 mg and 16 mg tablets have no available source reported from any manufacturer.

Don’t stop or change your therapy on your own — talk with your prescriber about the plan that fits you, and ask your pharmacist what’s actually available (see options).

Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →
4
Affected NDCs
1
Reporting manufacturers
0/1
Reporting mfrs supplying
0/4
Affected strengths supplied
161
Days in shortage
Source: FDA Drug Shortages Database API (openFDA). Last refreshed Sep 23, 2026 · today

What’s in shortage — at a glance

These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Tiagabine Hydrochloride Tablet. Other makers that haven’t reported a problem are shown in the green card below.

Availability of affected NDCs
From the FDA shortage report
4 NDCs
To be discontinued 4
Affected strengths still supplied
Among manufacturers reporting this shortage
0/4 strengths
No supply 4
FDA-reporting manufacturers with supply
Among manufacturers reporting this shortage
0/1 makers
No supply 1
✓ Other manufacturers not reporting a shortage
Still-marketed Tiagabine Hydrochloride Tablet from companies that have not filed an FDA shortage — these are not counted in the figures above. Stock can still vary by pharmacy.
Sun Pharmaceutical Industries, Inc. Cephalon, LLC Novadoz Pharmaceuticals LLC
See all other options & details →
Shortage timeline
  1. Apr 15, 2026
    Currently in shortage
    4 of 4 products affected.
  2. Apr 15, 2026
    First reported to the FDA
    4 products first listed.

Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.

What exactly is on backorder — by manufacturer

Manufacturer: Teva Pharmaceuticals USA, Inc. 📞 888-838-2872 4 NDCS click to expand
Status NDC / product Strength Availability Related information Reason
To Be Discontinued Tiagabine Hydrochloride, Tablet, 2mg 30 count (NDC 0093-5030-56) NDC 00093-5030-56 Discontinuation of the manufacture of the drug
To Be Discontinued Tiagabine Hydrochloride, Tablet, 4mg 30 count (NDC 0093-5031-56) NDC 00093-5031-56 Discontinuation of the manufacture of the drug
To Be Discontinued Tiagabine Hydrochloride, Tablet, 16mg 30 count (NDC 0093-8076-56) NDC 00093-8076-56 Discontinuation of the manufacture of the drug
To Be Discontinued Tiagabine Hydrochloride, Tablet, 12mg 30 count (NDC 0093-8072-56) NDC 00093-8072-56 Discontinuation of the manufacture of the drug

These rows are manufacturer reports to the FDA for Tiagabine Hydrochloride Tablet — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Tiagabine Hydrochloride Tablet? options further down this page.

Why is Tiagabine Hydrochloride Tablet in shortage?

Teva Pharmaceuticals has reported to the FDA that they are permanently stopping the manufacturing of their tiagabine hydrochloride tablets. This affects all four strengths they made — the 2 mg, 4 mg, 12 mg, and 16 mg tablets — all in 30-count bottles. This isn't a temporary delay or a supply hiccup; Teva has stated this is a full discontinuation of these products.

It's worth knowing that the FDA did not share a specific public reason for why Teva made this business decision. Also, this report only covers Teva's products — it doesn't speak to what other manufacturers may be doing with their own versions of this medicine.

Based on the manufacturer-reported reason(s) and notes on file with the FDA for Tiagabine Hydrochloride Tablet, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.

What should I do if I take Tiagabine Hydrochloride Tablet?

Tiagabine Hydrochloride tablets are currently on the FDA drug-shortage list, and I want to walk you through what this means so you can plan calmly.

This report covers all four strengths — 2 mg, 4 mg, 12 mg, and 16 mg (30-count bottles). Right now none of these strengths have an available source from the manufacturer that filed this report, Teva Pharmaceuticals. The reason given is that Teva is discontinuing manufacture of the drug. Because this is a discontinuation rather than a temporary delay, this particular supply may not return, so a conversation with your prescriber is a sensible next step. Keep in mind this report reflects only Teva — other makers may still supply this same medicine.

Please do not stop, skip, or change your dose on your own. Here is how to approach it:

  • Ask your pharmacy to check wholesalers and other manufacturers for your strength.
  • This same medicine (tiagabine) is also listed from Sun Pharmaceutical, Cephalon, and Novadoz. Your pharmacy may be able to source one of these, though it may not be in local stock right away.
  • If your exact strength cannot be found, ask your prescriber or pharmacist about options, such as a clinician-chosen alternative.

Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls.

This is general information from national FDA data and may not match your local pharmacy's actual stock.

See “Where else can I get Tiagabine Hydrochloride Tablet?” below ↓ The same medicine from manufacturers not reporting a shortage, alternative dosage forms, and therapeutic equivalents with pricing.
If you are a patient:
  • Don’t stop or change the medication on your own — talk to your prescriber first.
  • If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
  • Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
  • Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
Keep reading
Our full Tiagabine guide

Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.

Read the Tiagabine guide →

Where else can I get Tiagabine Hydrochloride Tablet?

FDA shortages are manufacturer-reported — a company only shows up on the shortage list if it told the FDA it has a supply problem, so not every maker of Tiagabine Hydrochloride Tablet is necessarily short. Below we pull together the other still-marketed options that are not reported in shortage: the same medicine from manufacturers that haven’t reported a problem, and alternative dosage forms. These may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.

Same medicine, other manufacturers (not reported short)

Same active ingredient, dosage form & route as the shortage (matched on the FDB HICL ingredient code), from makers that have not filed a shortage with the FDA:

ProductStrengthForm / routeManufacturerNDC
Tiagabine Hydrochloride TIAGABINE HYDROCHLORIDE 2 mg/1 Tablet, Film Coated · Oral Sun Pharmaceutical Industries, Inc. 62756-0200-18
Tiagabine Hydrochloride TIAGABINE HYDROCHLORIDE 4 mg/1 Tablet, Film Coated · Oral Sun Pharmaceutical Industries, Inc. 62756-0224-08
Tiagabine Hydrochloride TIAGABINE HYDROCHLORIDE 2 mg/1 Tablet, Film Coated Cephalon, LLC 63459-0402-30
Tiagabine Hydrochloride TIAGABINE HYDROCHLORIDE 4 mg/1 Tablet, Film Coated Cephalon, LLC 63459-0404-30
Tiagabine Hydrochloride TIAGABINE HYDROCHLORIDE 12 mg/1 Tablet, Film Coated Cephalon, LLC 63459-0412-30
Tiagabine Hydrochloride TIAGABINE HYDROCHLORIDE 16 mg/1 Tablet, Film Coated Cephalon, LLC 63459-0416-30
Tiagabine Hydrochloride TIAGABINE HYDROCHLORIDE 2 mg/1 Tablet · Oral Novadoz Pharmaceuticals LLC 72205-0084-30
Tiagabine Hydrochloride TIAGABINE HYDROCHLORIDE 4 mg/1 Tablet · Oral Novadoz Pharmaceuticals LLC 72205-0085-30
Tiagabine Hydrochloride TIAGABINE HYDROCHLORIDE 12 mg/1 Tablet · Oral Novadoz Pharmaceuticals LLC 72205-0086-30
Tiagabine Hydrochloride TIAGABINE HYDROCHLORIDE 16 mg/1 Tablet · Oral Novadoz Pharmaceuticals LLC 72205-0087-30
Therapeutic equivalents & pricing 8 productsclick to expand

Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.

ProductManufacturerPackageNADAC $/unitAB ratingAvailability
Tiagabine Hydrochloride 4 mgNDC 00093-5031-56 Teva 30 tablets $2.273 AB Availability likely
Tiagabine Hydrochloride 4 mgNDC 72205-0085-30 Novadoz 30 tablets $2.273 AB Availability likely
Tiagabine Hydrochloride 2 mgNDC 00093-5030-56 Teva 30 tablets $2.412 AB Availability likely
Tiagabine Hydrochloride 2 mgNDC 72205-0084-30 Novadoz 30 tablets $2.412 AB Availability likely
Tiagabine Hydrochloride 16 mgNDC 00093-8076-56 Teva 30 tablets $6.027 AB Availability likely
Tiagabine Hydrochloride 16 mgNDC 72205-0087-30 Novadoz 30 tablets $6.027 AB Availability likely
Tiagabine Hydrochloride 2 mgNDC 62756-0200-18 Sun 1000 tablets FDA listed
Tiagabine Hydrochloride 4 mgNDC 62756-0224-08 Sun 100 tablets FDA listed

Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.

Other drugs in the same treatment class

These are different medicines — not other versions of Tiagabine Hydrochloride Tablet — that fall in the same broad treatment class (anticonvulsants) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.

Identity & classification

GCN Seq No 044693
GCN 54681
HICL code 015773
Ingredient (HICL) Tiagabine Hcl
HIC1 code H
Therapeutic class — broad (HIC1) Nervous System (Except Autonomic)
HIC2 code H4
Therapeutic class — intermediate (HIC2) Anticonvulsants
HIC3 code H4B
Therapeutic class — specific (HIC3) Anticonvulsants
AHFS code 28:12.28.00
AHFS class Gaba-Mediated Anticonvulsants
FDB label name TIAGABINE HCL 2 MG TABLET
FDB brand name Tiagabine Hcl
Legend status F — Federal legend — prescription drug or device
GPI-1472170070100302
GPI classtiaGABine HCl
Where does this data come from?
Identity codes come from First Databank (FDB) (HICL ingredient, HIC1–3 therapeutic-class hierarchy, GCN, AHFS class, legend status) and Medi-Span GPI, mapped from a representative affected NDC. Licensed reference data — for identification only.

Other neurology shortages

Tiagabine Hydrochloride Tablet shortage FAQs

Is Tiagabine Hydrochloride Tablet in shortage?
Yes — the FDA currently lists Tiagabine Hydrochloride Tablet in shortage (status: “To Be Discontinued”, first reported Apr 15, 2026). 4 of 4 products are affected. This is national, manufacturer-reported data, so your pharmacy may still have stock.
Which products are affected?
Tiagabine Hydrochloride, Tablet, 2mg 30 count (NDC 0093-5030-56) (NDC 00093-5030-56); Tiagabine Hydrochloride, Tablet, 4mg 30 count (NDC 0093-5031-56) (NDC 00093-5031-56); Tiagabine Hydrochloride, Tablet, 16mg 30 count (NDC 0093-8076-56) (NDC 00093-8076-56). The full per-NDC list (availability, manufacturer and status) is in the table above — each NDC links to its own page.
When will Tiagabine Hydrochloride Tablet be available again?
The FDA does not publish a guaranteed restock date, and no estimated-recovery note is on file. Availability can change daily — confirm with your pharmacy.
Can I still get Tiagabine Hydrochloride somewhere?
Other manufacturers (Sun Pharmaceutical Industries, Inc., Cephalon, LLC, Novadoz Pharmaceuticals LLC) still market it and have not reported a shortage. See “Where else can I get Tiagabine Hydrochloride Tablet?” above — stock still varies by pharmacy.
What should I do if I take Tiagabine Hydrochloride Tablet?
Don’t stop or change it on your own. Ask your pharmacist whether they can order it from another manufacturer or a different strength/package size, and ask your prescriber about a long-term plan before your supply runs out.

Still have a question about the Tiagabine Hydrochloride Tablet shortage?

Ask a pharmacist about this shortage →
How to read the Supply-Risk rating
Low (1–2)Multiple manufacturers still supplying and most strengths or pack sizes sourceable.
Medium (3)Some constraint — fewer suppliers or a notable share of NDCs unavailable.
High (4–5)Down to a single source, most strengths or pack sizes unsourceable, or a long-running outage.
Where does this data come from?
Shortage records come from the FDA Drug Shortages Database API via openFDA (/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.
Data structure & sourcing designed and verified by Dr. Brian Staiger, PharmD.
← Back to all current drug shortages